ArticleJournal of translational medicine2012

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

George Fountzilas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.